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Malgorzata Drozniewska1,2* and Olga Haus1,3Abstract
Deletions of the PAX3 gene have been rarely reported in the literature. Mutations of this gene are a common cause
of Waardenburg syndrome type 1 and 3. We report a 16 year old female presenting hearing loss and normal
intellectual development, without major features of Waardenburg syndrome type 1, and without family history of
the syndrome. Her phenotype, however, overlaps with features of craniofacial-deafness-hand syndrome. Microarray
analysis showed ~862 kb de novo deletion at 2q36.1 including PAX3. The above findings suggest that the
rearrangement found in our patient appeared de novo and with high probability is a cause of her phenotype.
Keywords: PAX3 gene, Array-CGH, Hearing loss, Waardenburg syndrome, Craniofacial-deafness-hand syndromeBackground
Hearing loss is a common feature which can be present as
an isolated form or be one of an auditory phenotype
symptoms [1]. Inherited hearing loss can be transmitted
in an autosomal dominant, autosomal recessive, X-linked
or even in mitochondrial mode of inheritance. Although
most of hearing loss cases are nonsyndromic, accompany-
ing abnormalities can be present.
Hearing loss can be present in more than 400 genetic
syndromes. Waardenburg syndrome (WS) is the most
common type of hearing loss inherited as autosomal dom-
inant trait. Phenotype associated with this syndrome
includes, apart from hearing loss of various degree, pig-
mentary abnormalities of the skin, eye (heterochromia iri-
des or bright blue irides) and hair (white forelock). Four
types of WS have been distinguished, depending on the
presence of other abnormalities. Patients with WS type 1
(WS1) present mutation within Paired Box 3 (PAX3) gene,
however it has been shown to be present in only 45% of
the WS1 syndrome. Heterozygous mutations of this gene
have been reported in both sporadic and familial cases [1].
Up to date more than 100 PAX3 mutations have been re-
corded in the Human Gene Mutations Database, of which
about 50% are missense/nonsense mutations. Partial or* Correspondence: m.drozniewska@gmail.com
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article, unless otherwise stated.whole gene deletions have been reported in ~10% of pa-
tients [2,3]. Rare subtype, craniofacial-deafness-hand syn-
drome (CDHS), can also be caused by PAX3 mutations.
PAX3 gene belongs to the transcription factors paired
box family and has been mapped to chromosome 2q35.
As shown by Bondurand et al., PAX3, together with
SOX10, strongly activates microphtalmia-associated tran-
scription factor (MITF) and contributes to pigmentation
abnormalities [4].
We report on a female patient with congenital sensori-
neural hearing loss with minor facial dysmorphism partially
overlapping with features characteristic for Waardenburg
syndrome 1 and craniofacial-deafness-hand syndrome
in which PAX3 de novo deletion has been identified by
microarray analysis.Case presentation
Clinical report
The 16 years old girl was referred for genetic counselling due
to congenital hearing loss and subtle dysmorpic features.
The proband is the second child of non-consanguineous par-
ents. She has two healthy sisters. She was born at term
after an uneventful pregnancy. Her birth weight was
3200 g, length 53 cm. Apgar score was 10. Synophrys and
low set ears were noted at birth.
Her early psychomotor development was normal, with-
out any notable delay. Later she presented speech impair-
ment due to hearing problems, noted at the age of 2. She
attended a school for children with hearing impairment.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ology Unit due to hirsutism and hypercholesterolemia.
Physical examination revealed seborrheic dermatitis,
astigmatism, and profound sensorineural hearing loss.
Hirsutism was scored at 6 according to the Ferriman-
Gallwey scale. Sex hormone levels were normal.
Phenotype examination at the genetic counselling centre
revealed the presence of wide set eyes of brilliant blue iri-
des, dystopia canthorum, shortened upslanting palpebral
fissures, hypoplastic alae nasi, hirsutism (Figure 1). Please
note that synophrys is not visible as she keeps her eye-
brows plucked. She did not present white forelock char-
acteristic for WS, however it cannot be excluded that
she dyed her hair (despite denying it). Intellectual de-
velopment was normal. Both parents were phenotypic-




Chromosomal analysis was performed according to stand-
ard procedures on GTG-banded metaphase spreads, ob-
tained from peripheral blood lymphocytes.Figure 1 Facial appearance of the patient at the age of 16.
Note brilliant blue irides, hypertelorism, dystopia
canthorum, hirsutism.Array-CGH
An oligo array-CGH was performed using the Human
Genome CGH Microarray Kit and SurePrint G3 4x180K
Human Kit (Agilent Technologies, Santa Clara, CA, USA),
according to the manufacturer’s protocols. The Agilent Fea-
ture Extraction software has been used to perform image
analysis. Array data were compared with the human gen-
ome reference sequence hg19 (February 2009). Genomic
DNA was extracted from peripheral blood lymphocytes.
Method of confirmation (FISH)
Fluorescence in situ hybridisation (FISH) was performed
on metaphase spreads by using PAX3 Breakapart Probe
(Cytocell, Cambridge, UK) according to manufacturer’s
protocol. Metaphases were analysed with Nikon Eclipse
fluorescent microscope. Images were analysed and ar-
chived with Applied Spectral Imaging software (Applied
Spectral Imaging, Edingen, Neckerhausen, Germany).
Results
Cytogenetic GTG analysis revealed normal female karyotype.
Array CGH experiment disclosed an interstitial deletion
within long arm of chromosome 2. The deletion region
was found to be ~862 kb in size and ranged between oli-
gos 222,562,885-223,424,791 (UCSC Genome Browser on
Human, Feb. 2009 (GRCh37/hg19) Assembly). This re-
gion is localised within band 2q36.1 and contains PAX3
gene, CCSC140 gene and a part of SGPP2. Overview of
the deleted region, together with its aCGH profile is
shown on Figure 2.
FISH examination using PAX3 break apart probe con-
firmed the aCGH finding.
Combined parental follow-up by standard cytogenetics
and microarray testing showed no evidence of deletion of
2q36.1 in either parent. FISH studies using the same probe
excluded deletion or any balanced rearrangement involv-
ing 2q36.1 region. Figure 3 shows FISH results of the pro-
band (3A) and proband’s mother (3B).
Molecular investigation of GJB2 gene in the girl excluded
the presence of its most common mutation, del35G.
The above findings suggest that the rearrangement
found in our patient appeared de novo and with high
probability is a cause of her phenotype.
Discussion
We report a patient with a de novo 2q36.1 deletion of
862 kb, including PAX3 gene, which is a member of the
transcription factors family [4-6]. In humans, constitu-
tional mutations of PAX3 lead to Waardenburg syndrome
(WS) or Craniofacial-deafness-hand (CFDS) syndrome
[1,7]. Acquired mutations or rearrangements of PAX3
may cause alveolar rhabdomyosarcoma [5]. PAX3 gene
contains 10 exons and encodes protein of 98% homology
to the mouse orthologue [3,5].
Figure 2 Array-CGH profile using Agilent 180 K microarray showing deletion of 2q36.1 including PAX3 gene. Below – overview of the
deletion region.
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was first described by Sommer et al. in 1983 [7]. Several
follow-up studies were performed since, and genotype-
phenotype correlation was established.
Point mutations of PAX3 account for ~90% of WS1
and WS3 (Waardenburg Syndrome type 3) in patients
meeting clinical diagnostic criteria, whereas partial and
whole PAX3 deletions can be causal in only ~6% of cases
[8]. Diagnostic tests are based mainly on sequencing of
genes involved in WS etiology, however MLPA tech-
nique can also be of use [8,9].There are larger deletions of chromosome 2q recorded
in the Decipher database, which also include PAX3 gene.
Of these cases one shows similar phenotype to our pa-
tient, including synophrys, hypertelorism and iris pig-
mentation disturbances (ID: 248718). Deletion reported
in this patient is 4.95 Mb in size, and its size likely con-
tributes to other clinical features, such as intellectual
disability. Comparison of cases recorded in Decipher
database and this case is shown on Figure 4.
Previous reports suggested that PAX3 deletions did
not necessarily result in distinct WS phenotype, which
Figure 3 FISH results with PAX3 breakapart probe (Auqarius, Cytocell). A – patient’s metaphase spread. Arrows indicate fluorescent signals.
Yellow arrow shows normal chromosome 2 with both fluorescent signals present. Note absence of one red signal on one of the chromosomes 2,
indicated by green arrow. B – patient’s mother blood cell nucleus. Yellow arrows indicate fluorescent signals showing no deletion within
examined loci. The same signal pattern was observed in patient’s father. C – schematic overview of PAX3 probe (Vysis). Red bar represents
proximal region of probe coverage (observed as red signal), green bar – distal region (observed as green signal).
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ated variable phenotype. In addition authors suggested
that size of rearrangement can also affect manifestation
of WS clinical features [8], however no relationship was
found between severity of clinical features and the type
of mutation [3].Figure 4 Schematic comparison of 2q deletions including PAX3 record
deletion seen in our patient is represented by blue bar. Red bars representIt is not possible to make a strict correlation between
our patient’s phenotype and either WS or CFDS. The diag-
nosis of Waardenburg syndrome can be made when at
least two major or one major and two minor phenotypic
criteria are met. Presence of dystopia canthorum and
hearing loss (major criteria) together with synophrys,ed in the Decipher database and presented case. Region of
Decipher cases. ID numbers are shown on sidebar.
Table 1 Review of clinical features present in our patient






Gad et al. [1]
Flat facial profile - + +




Heterochromia of irides - - -
Synophrys + - -
Depressed nasal bridge - + +
Contractures of digits - + +
Hirsutism + - -
Normal intelligence + + +
Hearing loss + + +
Pigmentation abnormalities - - -
Dystopia canthorum + - -
Brilliant blue irides + - -
Legend: (+) presence of feature, (−) absence of feature.
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could be convincing enough to make a diagnosis of WS1.
However, comparison of the phenotypes of the two syn-
dromes suggests that the patient could also be qualified as
having craniofacial-deafness-hand syndrome. Despite dif-
ferent type of genomic changes described in our patient
and patients reported in the literature, similar dysmorphic
features and normal intellectual development can lead to
conclusion that these patients can be classified into the
same group. Comparison of clinical features present in de-
scribed case and in patients reported by Sommer and Bar-
tholomew [7] Gad et al. [1] is shown in Table 1.
Further molecular analysis of the second allele is to be
considered in terms of any mutations present.Conclusion
In conclusion, our case can be another example of PAX3
rearrangement causing distinct but variable phenotype.
It also shows that it may be recommended to perform
array-CGH analysis in addition to PAX3 mutations ana-
lysis in the patients with hearing loss and dysmorphy.Consent
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